Skip to content

Evaluation Of The Efficacy Of Subgingival Application Of Lovastatin Gel As An Adjunct To Non-Surgical Treatment Of Periodontitis In Generally Healthy Smokers And Non-Smokers Patients in Central Europe.

Assessment of Changes in Clinical and Radiological Parameters in Gingival Pockets After Subgingival Application of Lovastatin Gel in Combination With SRP Procedure Compared to SRP and Placebo Gel Application in the Treatment of Periodontal Disease in Generally Healthy Non-smokers and Smokers From Central Europe: a Split-mouth Randomized Controlled Trial.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07282756
Acronym
RCT
Enrollment
44
Registered
2025-12-15
Start date
2025-07-11
Completion date
2026-12-01
Last updated
2026-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontal Disease, Periodontal Diseases, Periodontitis, Smokers

Keywords

periodontitis, statins, lovastatin, smoking, periodontal disease

Brief summary

The aim of the study is to evaluate how a gel (1.2% lovastatin) applied under the gum improves the results of classic periodontal treatment (SRP-scaling, root planing). The study involves two groups of adults diagnosed with periodontitis: the first group consists of generally healthy individuals who do not smoke tobacco. The second group consists of generally healthy individuals who have been smoking for at least 5 years. Before the study begins, each participant will undergo gum health measurements. Changes in these parameters will be monitored throughout the study. Two teeth will be selected for each participant: * a gel containing the medication will be applied under the gum of one tooth * a gel that looks similar to the medication but does not contain any medicinal substance will be applied under the gum of the second tooth. Before applying the gel, each participant will undergo subgingival cleaning (SRP) to remove any debris that may prevent the medicine from working. The study will last six months. Expected results: * all participants will experience an improvement in the condition of their gums after treatment * the effect of treatment will be better in non-smokers than in smokers * the treatment outcome will be better in the area where the medicated gel was applied compared to areas where the gel without medicinal substances was applied.

Interventions

DRUGSubgingival application of 1.2% lovastatin

Each patient will be assigned 2 sites that meet the inclusion criteria. After the SRP (scaling, root planing) procedure is applied within the qualified gingival pockets, a gel drug (1.2% concentration of lovastatin) will be applied to one site selected by randomization.

DRUGSubgingival application of placebo gel

Each patient will be assigned 2 sites that meet inclusion criteria. After the SRP procedure (scaling, root planing) procedure is applied within qualified gingival pockets, placebo gel will be applied to one site selected by randomization.

Sponsors

Medical University of Silesia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Intervention model description

After the SRP procedure is applied within the qualified gingival pockets, a gel drug (1.2% concentration of lovastatin) will be applied to the first designated site, and a placebo gel (split-mouth design) will be applied to the second site.

Eligibility

Sex/Gender
ALL
Age
18 Years to 59 Years
Healthy volunteers
No

Inclusion criteria

* generally healthy patients * diagnosed periodontal disease (at least one pair of non-adjacent sites with PD≥5 mm or CAL ≥4 mm and vertical bone loss ≥ 3 mm) * no history of periodontal disease treatment * no history of antibiotic use in the past 6 months * an eligible tooth must be alive, with no history of endodontic treatment * non-smoking (group I) or active smokers (group 2)

Exclusion criteria

* Statin allergy * receiving systemic statin therapy, * alcoholics * immunocompromised patients * pregnant or breastfeeding women.

Design outcomes

Primary

MeasureTime frameDescription
Clinical Attachment Levelchange from baseline to 6 months after interventionthe distance between the enamel-cement junction (CEJ) and the bottom of the gingival pocket; expressed in mm
Probing Depthchange from baseline to 6 months after interventionthe distance between the gingival margin and the bottom of the gingival pocket, measured with a calibrated periodontalprobe, expressed in mm
modified Sulcus Bleeding Index (mSBI)from baseline to six months after interventionan index used to determine the severity of inflammation in the periodontal tissues; determines the percentage of the study area that is inflamed. Expressed as a percentage, where 0% indicates no inflammation and 100% indicates maximum inflammation.
Plaque Index Pl.I. (Silness i Löe)from baseline to 6 months after interventionan index that evaluates the patient's level of oral hygiene on a numerical scale of 0-3. Optimal hygiene occurs at values \<1, while values \>1 indicate insufficient hygiene that needs improvement. The higher the value, the worse the hygiene.

Secondary

MeasureTime frameDescription
Infrabony Defect Depthfrom baseline to six months after interventiona parameter measured as the distance from the edge of the alveolar crest to the bottom of the bony defect; assessed on conebeam computed tomography (CBCT) scanning

Countries

Poland

Contacts

CONTACTMagdalena Pietrzko, DMD
pietrzkoperio@gmail.com+48604796143
CONTACTRafał Wiench, profesor
rwiench@sum.edu.pl

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026